High expression of transferrin receptor (TfR) on the membrane of erythroid cells accounts for the high level of iron required to sustain heme synthesis. Several studies indicate that during erythroid differentiation TfR expression is highly dependent on transcriptional regulation. In this study we characterized the minimal region able to confer transcriptional regulation during erythroid differentiation in Friend leukemia cells (FLC). This region of 120 bp, upstream the transcription start site, contains an overlapping consensus recognition sequence for AP1/CREB/ATF transcription factors and for proteins of the Ets family and a GC rich region. Here, we report that both the Ets and the Ap1/CRE like sites are essential for promoter activity during erythroid differentiation. We showed that Ets-1 binds to the EBSTfR and its binding activity decreases in FLC induced to differentiate and during normal erythroid differentiation. Consistent with this, FLC constitutively expressing Ets-1 show a decrease in TfR gene expression, globin mRNA and hemoglobin synthesis. We conclude that Ets-1 binding activity is modulated during erythroid maturation and that a deregulated expression of this transcription factor interferes with terminal erythroid differentiation.
Introduction
The Ets proteins constitute a highly conserved gene family of winged helix turn helix transcription factors which have been implicated in regulation of gene expression during a variety of biological processes such as differentiation, development and tumorigenesis. The Ets family of transcription factors, comprising more than 30 different members is characterized by the presence of an 85-aminoacid sequence termed the 'Ets domain' that is highly conserved from lower metazoans to humans. Through this domain the Ets proteins bind to specific purine-rich DNA sequence containing a conserved core motif of GGAA/T in the middle of 10 base pairs (bp) of DNA. These flanking sequences are variable and there is evidence that they help to determine which Ets proteins will bind (reviewed in Wasylyk et al., 1993; Wasylyk and Nordheim, 1997; Watson and Seth, 2000) . Ets-1 is the founding member of the Ets family and was initially identified as the protooncogene corresponding to the v-Ets oncogene of the E26 leukemia virus. In humans, Ets-1 is expressed at high levels in proliferating vascular endothelial cells of the embryo and in blood vessels of the adult during angiogenesis (Wernert et al., 1992) . In the hematopoietic system the analysis of targeted mutants has revealed an essential role for Ets-1 in the differentiation of all lymphoid cells; it was found to be essential for the development of functional NK cells (Barton et al., 1998) and for survival and maturation of B and T cell lineages (Bories et al., 1995; Muthusamy et al., 1995) . Conversely, the role of Ets-1 in the other lineages of the hematopoietic system is not yet clarified and it is still debated whether Ets-1 acts as a transcriptional activator or an inhibitor of erythroid differentiation.
The transferrin receptor (TfR) is a transmembrane, homodimeric glycoprotein, which mediates cellular iron uptake by the binding and internalization of ironloaded transferrin. TfRs are expressed on nearly all cell types of higher organisms but their number is highly variable. TfRs are highly expressed on the membrane of immature erythroid cells and in rapidly dividing cells (reviewed in Ponka, 1997; Ponka and Lok, 1999) .
In most cell types it has been clearly established that TfR expression can be enhanced by decreased intracellular iron, via a post-transcriptional mechanism (Ponka, 1997; Klausner et al., 1993; Hentze and Kuhn, 1996) ; however, in differentiating erythroid cells, where high levels of iron are required for heme-synthesis during hemoglobinization, transcriptional mechanisms (Chan et al., 1994; Busfield et al., 1997; Marziali et al., 1999; Lok and Ponka, 2000) cooperate with posttranscriptional mechanisms to induce high level of TfR expression (Weiss et al., 1997) . The elements of the TfR promoter, through which basal and cell growth dependent TfR transcription is regulated, have been partially characterized and comprise an AP1-like sequence, a GC rich region (Casey et al., 1988; Beard et al., 1991; Ouyang et al., 1993; Hirsch and Miskimins, 1995) and the recently identified hypoxia response element Tacchini et al., 1999) . Less characterized are the cis-acting elements and the transcription factors responsible for transcriptional activation of the TfR gene during erythroid differentiation, when TfR transcription remains elevated also in growth arrested cells. We previously showed that a proximal promoter region of about 300 bp upstream of the TATAA box was responsible for transcriptional regulation in response to dimethylsulphoxide (Me 2 SO) in FLC but not in NIH3T3 cells (Marziali et al., 1999) . In line with recently published data (Lok and Ponka, 2000) , here we show that a minimal region of 120 nucleotides from the transcription start site is responsible for TfR transcriptional regulation during erythroid differentiation. This region is the same involved in TfR growth-dependent transcription and contains a GC-rich sequence, a recognition sequence for both AP1 and CREB/ATF families of transcription factors and an Ets binding site (EBS) . In this study we show that Ets-1 binds to the EBS-TfR and its binding activity is downmodulated during erythroid differentiation of both cell lines and primary human erythroblasts. Consistent with this observation, enforced expression of Ets-1 in FLC and K562 cells leads to an impairment of the differentiation process with a reduction in TfR gene expression, globin mRNA and hemoglobin production.
Results

Functional analysis of the proximal region of the TfR promoter
To identify the cis-elements responsible for TfR transcriptional activation in differentiating FLC, fragments of 7300 and 7120 bp of the proximal TfR gene promoter were cloned upstream the luciferase reporter gene and transiently transfected in FLC. After transfection, cells were split to standardize the transfection efficiency and treated for 48 h with control medium and either 1.5% Me 2 SO or 5 mM hexamethylene-bisacetamide (HMBA). As shown in Figure 1a , both constructs were equally stimulated by 6 -8-fold after 48 h of Me 2 SO or HMBA treatments, indicating that the first 120 bp from the transcription start site are sufficient to confer responsiveness to inducers of differentiation in FLC. The same constructs transfected in NIH3T3 cells were not affected by the chemical treatments (Marziali et al., 1999 and data not shown). The 7120 bp fragment of the TfR gene promoter contains a GGAA sequence (EBS), known to bind proteins of the Ets family, overlapped with a sequence similar to the consensus binding sites for the AP1/ CREB/ATF (TGACGCA) transcription factors and a GC-rich region. To identify the sites critical for TfR transcription during erythroid differentiation, the EBS, AP1/CRE and GC sites were mutated, individually or in combination, by site direct mutagenesis and tested by transient transfections in FLC. The 740 bp luc construct, which contains the TATAA box alone, was used as a control for specificity. As shown in Figure  1b , disruption of the EBS site resulted in a 2.5-fold increase of TfR promoter basal transcription, whereas the induction of the promoter activity after Me 2 SO treatment was comparable to that observed for the wild type promoter. Conversely, elimination of the Figure 1 Characterization of the cis-acting elements involved in TfR transcriptional regulation during erythroid differentiation. (a) FLCs were transiently transfected with constructs containing the 7300 or 7120 bp TfR promoter fragment linked to the luciferase reporter gene. After transfection, cells were split and treated for 48 h with medium alone and either 1.5% Me 2 SO or 5 mM HMBA. Luciferase activity was measured and values were reported as n-fold of induction with respect to cells treated with control medium alone. (b) FLC were transiently transfected with the wild type 7120 bp promoter fragment linked to the luciferase reporter gene or with the same construct mutated in the EBS, in the AP1/CRE sites and in the GC rich sequence, alone or in combination. A 740 bp construct was transfected as control for specificity. In the lower panel the sequences of the mutated constructs are shown. Transfected cells were treated with medium alone or with 1.5% Me 2 SO for 48 h AP1/CRE site inhibited of about threefold the promoter activity induced by Me 2 SO. When both the EBS and AP1/CRE sites were disrupted, the Me 2 SOdependent activation of TfR transcription was almost completely abolished. Mutation in the GC-rich sequence did not significantly affect promoter activity. These results indicate that the EBS seems to affect only basal promoter activity, whereas the AP1/CRE-like sequence is important in mediating Me 2 SO inducible transcription. Both sites are, however, required to confer full transcriptional inducibility to the TfR promoter in response to Me 2 SO. Overlapping results were obtained when HMBA was used as a different inducer of erythroid differentiation (data not shown).
Analysis and characterization of the trans-activating factors binding to the proximal region of the TfR gene promoter
To identify the trans-activating factors able to bind to the regulatory region of the TfR promoter, whole cell extracts prepared from control FLC and FLC induced to erythroid differentiation were incubated with labeled double-stranded EBS/AP1/CRE oligonucleotide and analysed by electrophoretic mobility shift assay (EMSA). As shown in Figure 2 , at least six complexes (C1-C6) were observed. Competition assay performed with 200-fold molar excess of unlabeled EBS/AP1/CRE (lane 6) oligonucleotide showed that the C3 and C5 complex(es) were not competed, indicating a nonspecific binding. The slower migrating complexes (C1/ C2) reproducibly increased along the differentiation process, whereas the faster migrating complex (C6) decreased during erythroid maturation, being almost not detectable after 72 h of Me 2 SO treatment ( Figure  2, lane 4) . Interestingly, when the same probe was incubated with cell extracts from NIH3T3 cells, only one major DNA-protein complex was obtained ( Figure  2, lanes 8, 9) , specifically inhibited by the addition of anti c-Jun (lane 10) but not by anti c-fos antibodies (data not shown). The same antibodies were not able to affect the binding of any of the complexes obtained with cell extracts from FLC (data not shown).
In line with data recently published on the same sequence (Lok and Ponka, 2000) , complex C1/C2 was partially competed by oligonucleotides harboring the consensus recognition sequence for Ets factors (Ets cs lane 5) and for CREB/ATF family members (lane 7), but not by an excess of a consensus AP1 sequence (data not shown). The faster migrating complex (C6) was competed by the oligonucleotide harboring the consensus recognition sequence for Ets factors (Ets cs, lane 5). Several members of the Ets family could bind to the EBS-TfR, including PU.1 and Fli-1 which have been shown to interfere with erythroid differentiation (Starck et al., 1999) . However, among the Ets consensus oligonucleotides used for competition assay, only the Ets cs which harbors a consensus sequence preferentially bound by some Ets factors, such as Ets-1/2 and PEA3, resulted in the inhibition of C6 complex. Moreover, PU.1 or Fli-1 binding to EBSTfR was also excluded because either anti-PU.1 or anti-Fli-1 antibodies failed to affect complex formation (data not shown). Since it has been shown that Ets-1 binds to the TfR promoter in early chick erythroblasts (Sieweke et al., 1996) , supershift experiments with an antibody specifically recognizing Ets-1 were therefore performed. Indeed this antibody was able to partially shift the C6 complex ( Figure 3a , lane 2) and in line with this result, a recombinant purified Ets-1 protein, incubated with the linked EBS/AP1/CRE sites, showed a complex with similar mobility of C6 ( Figure 3a , lane 3).
To better analyse Ets-1 binding to the EBS-TfR, a labeled double-stranded oligonucleotide containing only the Ets site (EBS-TfR probe), whose sequence is indicated in Materials and methods, was incubated with whole cell extracts from FLC. A major complex was resolved by EMSA ( Figure 3b , lane 1) which was supershifted by the antibody specifically recognizing Ets-1 (Figure 3b , lane 3), but not by a pre-immune serum ( Figure 3b , lane 2). These results confirm that Ets-1 binds to the EBS in the TfR promoter.
Ets-1 binding activity decreases during erythroid differentiation
Results shown in Figures 2 and 3 indicate that Ets-1 binding decreases along the differentiation process. To further investigate this point, kinetic studies were performed incubating the labeled EBS-TfR oligonucleotide with cell extracts from both differentiating FLC and primary human erythroblasts. EMSA analysis, shown in Figure 4a , indicated that Ets-1 binding activity was downmodulated along the differentiation process in FLC either by Me 2 SO (lanes 1 -5) or HMBA (data not shown). The same behavior was observed in human erythroblasts prepared from purified human hematopoietic progenitors (HPCs) cultured under conditions that allow their selective growth along the erythroid lineage. During the first 8 -10 days of culture, HPCs differentiate to late erythroid progenitors, CFU-E (colony forming unit-erythroid). From days 10 to 20, the cells undergo a progressive maturation moving through different stages including proerythroblasts, basophilic erythroblasts, polychromatophilic erythroblasts and finally orthochromatic erythroblasts. At day 20 of culture the majority of the cells (i.e. 470%) correspond to late, mature orthochromatic erythroblasts. Cell extracts from these cells at different time points of culture, when incubated with the EBS-TfR, formed a complex of mobility similar to that obtained with FLC cell extracts (lane 6 -11). This complex was supershifted by the specific Ets-1 antibody (lane 12) and its binding activity progressively decreased during erythroblast maturation similarly to what was observed in chemically induced FLC. The highest level of activity was observed at day 5 of culture, when erythroid cells correspond to the stage of late erythroid progenitors (CFU-E), whereas the lowest one was at days 15 -20 of culture when cells move to terminal maturation stages (lanes 6 -11). The slightly faster migration of the complex was due to the different molecular weight of the human protein versus the murine one.
To investigate whether the decreased binding of Ets-1 to the TfR promoter was due to differences in the protein quantity, Western blot analysis was performed with equivalent amounts (50 mg) of whole cell extracts from untreated and Me 2 SO-treated FLC and erythroid culture at different stages of maturation. As shown in Figure 4b , the amount of Ets-1 protein did not vary either in Me 2 SO-treated cells or during normal human erythroblasts maturation, indicating that a post-transcriptional modification may be responsible for the decreased binding activity along the differentiation process. Therefore, to assess whether different cytoplasm/nucleus localization could account for Ets-1 activity regulation, Western blot analyses were performed on subcellular fractions. As shown in Figure  4c , in FLC, Ets-1 was predominantly localized in the cytoplasm, but after the Me 2 SO treatment the low amount of the protein present in the nucleus was further reduced. This result, together with data obtained in Ets-1 overexpressing cells (see Figure 4c and below), indicates that a different subcellular localization can be involved in Ets-1 activity regulation.
Ets-1 overexpression inhibits FLC differentiation program
The previous results support the hypothesis that Ets-1 has to be downmodulated during erythroid maturation to allow optimal TfR expression. To better define the role of Ets-1 along erythroid differentiation, FLCs constitutively expressing Ets-1 were generated. Two different pools (Ets-1A and Ets-1B) derived from two independent transfection experiments were considered. RNase protection assays (Figure 5a ) showed a sustained expression of the exogenous human Ets-1 mRNA in these two different pools (Ets-1A, lane 2 and Ets-1B, lane 3). Western blot analysis utilizing an anti Ets-1 antibody specifically recognizing the human protein, similarly confirmed the expression of the transfected gene (Figure 5a) . Moreover, as shown in Figure 4c , the overexpressed protein was mainly localized in the nucleus as compared with FLC w.t.
To test the effects of constitutive Ets-1 expression, FLC w.t. or transfected with the empty Rc/CMV vector and Ets-1 stably-expressing FLC were transiently transfected with the 7120 bp-luc construct and luciferase activity was measured in cell extracts from control cells or cells treated for 48 h with 1.5% Me 2 SO. As shown in Figure 5b , after the Me 2 SO treatment, Rc-CMV/FLC (lanes 1 and 2) and FLC w.t. (data not shown) showed an increase in promoter activity comparable to that shown in Figure 1a . Conversely, in stably Ets-1 expressing cells, a decrease of about 40% in the promoter responsiveness to Me 2 SO was observed (Figure 5b, lanes 3 and 4) . The effect of Ets-1 on TfR expression was then investigated. In line with transcription data, Northern blot analysis of mRNA extracted from w.t. and Ets-1-expressing FLC (Ets-1A) at different times after Me 2 SO addition, indicated that Ets-1 overexpression resulted in a reduction of TfR mRNA of more than 30% at 48 h, as compared to w.t. cells (Figure 6a) . A further decrease in TfR mRNA levels was observed at later times of treatment (data not shown). The reduction in TfR protein content was even more 1, 2) or FLC stably expressing Ets-1 (lanes 3, 4) were transiently transfected with the 7120 bp TfR promoter construct. After transfection both cell types were treated for 48 h with 1.5% Me 2 SO (FLC lane 2, FLC/Ets-1 lane 4). Whole cell extracts were prepared and assayed for luciferase activity. Values were reported as n-fold of induction with respect to basal activity of the construct in wild type FLC Ets-1 and transferrin receptor regulation in erythroid cells G Marziali et al evident as assessed by TfR protein expression on the cell membrane. Flow cytometry studies indicated that the basal level of TfR expression was higher in w.t. FLC and FLC transfected with empty vector as compared to that observed in Ets-1-expressing cells ( Figure 6b ). As expected, untreated cells both FLC (w.t. and Rc-CMV) and Ets-1 pools, exhibited a progressive decline in the TfR expression from day 1 to day 4, reflecting the decline in the proliferation rate as cells reach a high cell density. Conversely, control cells treated with Me 2 SO showed a progressive and substantial increase in TfR expression which was almost completely inhibited (70% of inhibition at day 4) in Ets-1-expressing FLC induced to differentiate. These results suggest that a constitutive expression of Ets-1 inhibits the up-regulation of TfR expression observed during erythroid maturation, but does not affect the growth-dependent regulation of TfR expression.
The effect of Ets-1 overexpression on other markers of erythroid differentiation was also investigated. The increase in globin mRNA and Hb accumulation, typically associated with the Me 2 SO treatment, was thus evaluated both in control and in Ets-1-expressing FLC. As shown in Table 1 , FLC induced to differentiate by Me 2 SO or HMBA exhibited the expected increase in the number of benzidine positive cells (B + ) from 2.5 to *81% and from 3% to 90% respectively, starting from 24 to 96 h of treatment. When cells with constitutive Ets-1 expression were analysed, no B + cells were obtained after 24 h of Me 2 SO or HMBA treatment and a reduction of *40% in B + cells was observed at 96 h as compared to w.t. cells. To investigate whether this reduction in hemoglobin synthesizing cells was associated with a reduction in the globin mRNA expression, Northern blot analysis was performed. As shown in Figure 7 , the increased levels of a-globin mRNA observed in w.t. FLC induced to differentiate were substantially reduced (*50%) in Ets-1-expressing FLC, indicating that constitutive Ets-1 expression exerts an inhibitory effect not only on TfR accumulation but also on other genes involved in erythroid differentiation. Consistently, morphological analysis provided evidence that Rc-CMV/FLC undergo maturation up to the stage of orthochromatic erythroblasts following Me 2 SO treatment, while the majority of FLC/Ets-1A cells remained blocked at the stage of basophilic erythroblasts (Figure 8a ). The levels of Ets-1 binding activity at various times after Me 2 SO stimulation, were quantitated by densitometric scanning and plotted with the mean values of B + cells as 'bonafide' content of the hemoglobin. The inverse correlation between the decrease of Ets-1 binding activity and the increase in hemoglobin content during erythroid differentiation is represented in Figure 8b .
Ets-1 overexpression inhibits erythroid differentiation and TfR expression in K562 cells
As a consequence of Friend virus transformation, FLC (745-A) express high levels of PU.1 and Fli-1, two members of the Ets family which can interfere with erythroid differentiation. Although supershift experiments (not shown) indicated that PU.1 and Fli-1 cannot directly bind to EBS-TfR, to exclude an indirect interference by competition for cofactors with Ets-1, we tested the effect of Ets-1 overexpression also in a different cell system, i.e. K562. K562 are human erythroleukemic cells in which no deregulated expression of Ets factors has been described and that can be induced toward an erythroid phenotype by treatment with sodium butyrate (NaB). K562 transduced with an empty retroviral vector Pinco (Pi) (Grignani et al., 1998) or Pinco vector expressing Ets-1 linked to the green fluorescent protein (GFP) were selected according to GFP positivity by FACS analysis, to obtain a homogeneous population of transduced K561/Pi and K562/Ets-1 cells, respectively. Ets-1 overexpression in stably transduced K562 cells from two different independent infections was evaluated by Western blot analysis (Figure 9a ). K562 w.t., K562/Pi and K562/Ets-1 were incubated for 72 h in the presence of 1 mM NaB or medium alone and analysed for differentiation markers expression by immunofluorescence and morphological analyses. Immunophenotypic analysis of control and NaB-treated cells showed a reduced expression of the erythroid markers glycophorin A and TfR in Ets-1-expressing cells as compared to cells transduced with the empty vector (Figure 9b ). Morphological analysis confirmed this observation, showing that Ets-1 overexpressing K562 cells remained immature after NaB treatment (Figure 9c ).
Discussion
Increasing evidence indicates that in erythroid cells, which need high levels of iron to sustain hemoglobin synthesis, the elevated expression of TfR is mainly dependent on transcriptional regulation (Chan et al., 1994; Busfield et al., 1997; Marziali et al., 1999; Lok and Ponka, 2000) . We previously showed (Marziali et al., 1999 ) that a promoter region of about 300 bp upstream of the transcription start site was responsible for transcriptional regulation of the TfR gene in response to Me 2 SO in FLC, but not in NIH3T3 cells. Extending our analysis and in line with recently published results (Lok and Ponka, 2000) , we found that the proximal 120 bp are sufficient for transcriptional regulation of TfR during erythroid differentiation. This region contains a GC-rich sequence, an AP1/CRE like sequence and an adjacent Ets binding site. The same region has also been involved in cell-growth dependent TfR transcription in non erythroid cells; however, here we show that the DNA binding factors that recognize this sequence in erythroid cells seem to be distinct from those observed in non erythroid systems (Figure 2) .
Transfection experiments indicate that the linked EBS and AP1/CRE sites are necessary for full TfR transcriptional regulation during erythroid differentiation (Lok and Ponka, 2000) . However, in our hands, disruption of the EBS site alone only slightly affects 
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Figure 7 a-globin mRNA expression is decreased in Ets-1-expressing FLC. Total RNA was purified at different times after Me 2 SO treatment and analysed by Northern blot, with 32 Plabeled cDNA probes for a-globin and b-actin Ets-1 and transferrin receptor regulation in erythroid cells G Marziali et al responsiveness to inducers of differentiation, whereas it clearly enhances basal transcription. Our transfection experiments suggest that the factor(s), which bind to the EBS, could exert an inhibitory effect on the promoter activity. The EBS is bound by members of the Ets family of transcription factors most of which have been implicated in differentiation, development and tumorigenesis (Watson and Seth, 2000) . To date, deregulated expression of two members of the Ets family, PU.1 and Fli-1, has been shown to interfere with terminal differentiation of erythroblasts (Starck et al., 1999; Pereira et al., 1999) . In particular, PU.1 expression is downregulated by Me 2 SO treatment and its overexpression has been shown to abolish globin mRNA induction in Me 2 SO treated MEL cells (Rao et al., 1997; Yamada et al., 1997) . We were unable to detect neither PU.1 nor Fli-1 binding using commercially available antibodies but instead we showed that the EBS-TfR is occupied by Ets-1 and its binding activity is downmodulated during chemical-induced erythroid differentiation of FLC and during normal erythroid maturation. This decline in Ets-1 binding activity may therefore explain why mutations of the EBS site alone does not affect Me 2 SO responsiveness and suggests that Ets-1 overexpression could interfere with terminal erythroid differentiation. Remarkably, all these data were confirmed using two different inducers of differentiation such as Me 2 SO and HMBA and different erythroid systems (i.e. FLC and K562 cells). Despite the extensive work on Ets-1, its role during erythroid differentiation is still debated. Several observations suggest that Ets-1 plays a role in early erythroid differentiation, since it is detected in erythroblasts of early yolk sac of the chick embryo (Que´va et al., 1993) . It has also been shown that Ets-1 overexpression slightly increases the amount of embryonic hemoglobins induced in K562 and HEL cell lines by hemin (Clausen et al., 1997) , that it is capable of activating promoters of erythroid genes and is involved in the activation of the TfR in early chick erythroblasts (Seth et al., 1993; Sieweke et al., 1996) . On the other hand, in contrast with these results, other studies indicate that the v-Ets binding domain is required to maintain multipotency of chicken hematopoietic progenitors transformed by myb-Ets (Kraut et al., 1994) and selectively inhibits differentiation of these progenitors along the erythroid lineage (Rossi et al., 1996) . Accordingly, the inactivation of Ets-1 expression was suggested to be required for erythroblastic differentiation (Kulessa et al., 1995) . Our results are in line with these latter observations and indicate that Ets-1 activity decreases during the maturation process of primary human erythroblasts and that its constitutive expression results in impaired erythroid differentiation, as demonstrated by the substantial decrease in TfR gene expression, globin mRNA and hemoglobin synthesis. We can thus speculate that Ets-1 may play a role in early steps of erythroid commitment and/or differentiation but, as differentiation proceeds, its downregulation is required for optimal erythroid maturation. Although we have not yet extensively investigated the mechanism responsible for the downregulation of Ets-1 DNA binding activity, we found no significant variations in the amount of the total protein during erythroid maturation, suggesting that downregulation of Ets-1 activity may be due to posttranslational modifications. According with this hypothesis a different subcellular localization both in differentiating and in Ets-1 overexpressing cells was indeed observed (Figure 4c) . Anyway, this observation did not exclude that other modifications, such as phosphorylation, which is known to repress Ets-1 DNA binding capacity (Cowley and Graves, 2000) can similarly occur during erythroid differentiation. Our results also suggest that another protein of the Ets family is probably involved in TfR regulation during erythroid differentiation. In fact, the linked EBS-AP1/CRE sites, which are essential for TfR transcriptional regulation, bind several complexes, one of which (C1/C2) is upregulated by the Me 2 SO treatment. We did not find evidence for binding of any erythroid specific transcription factors to this region, such as NF-E2, which can bind to DNA sequences similar to the consensus recognition motifs for AP1 (not shown). Although we were not able to determine the composition of this complex, it was partially competed by oligonucleotides harboring the consensus recognition sequence for CREB/ATF family members and for Ets proteins (Lok and Ponka, 2000) . Since enforced expression of Ets-1 has a negative effect on TfR transcription and its binding to the EBS is downmodulated during the progression of normal erythroid maturation, we argue that C1/C2 complex should contain an Ets family transcription factor other than Ets-1. It is thus tempting to speculate that induction of erythroid differentiation is coupled with Ets-1 downregulation that allow DNA accessibility to another transcription factor, probably belonging to the Ets family, but with different activity. This suggestion is in line with recent observations showing that hematopoietic transcription factors can be engaged in multiple protein-protein interactions. Starting from an initial protein complex in an early progenitor, individual factors are successively replaced during maturation, resulting in complexes with new properties that characterize different cell types and differentiation stages (Sieweke and Graf, 1998) .
Materials and methods
Cell cultures and treatments
FLC cells, clone 745-A, were grown in RPMI 1640 medium supplemented with 5% fetal calf serum (FCS) and antibiotics. FLC were seeded at 10 5 /ml and treated for the indicated times with either 1.5% dimethylsulfoxide (Me 2 SO, Sigma) or 5 mM hexamethylene-bisacetamide (HMBA, Sigma) to induce erythroid differentiation. The degree of differentiation was determined by evaluating the percentage of benzidine positive (B + ) cells according to Orkin et al. (1975) . K562 cells were cultured in RPMI medium supplemented with 10% FCS. K562 were seeded at 10 5 /ml and treated with cell culture grade 1 mM sodium butyrate (NaB, Upstate Biotechnology) to induce erythroid differentiation.
HPC purification
Adult peripheral blood (PB) was obtained from healthy donors after informed consent. Adult PB human progenitors cells (HPC) were purified according to a modification of the method reported by Gabbianelli et al. (1990) . Purified human hematopoietic progenitors were grown in serum-free medium containing BSA (10 mg/ml), pure human transferrin (1 mg/ ml), human low-density lipoproteins (40 mg/ml), insulin (10 mg/ml), sodium pyruvate (10 74 M), L-glutamine (2610 73 M), rare inorganic elements supplemented with iron sulfate (4610 78 M) and nucleosides (10 mg/ml each). HPC were induced to specific erythroid differentiation with 0.01 U/ ml IL-3, 0.001 ng/ml granulomonocytic colony stimulating factor (GM-CSF), 10 ng/ml Kit Ligand and 3 U/ml erythropoietin (EPO) (erythroid standard medium) (Sposi et al., 1992 ) (all materials were purchased from R & D Systems). Cells were harvested at different days, smeared on glass slides by cytospin centrifugation, and stained with MayGru¨nwald-Giemsa.
Plasmids and mutagenesis
To generate the 7120 bp pxp1luc plasmids, the 300 bp construct (Marziali et al., 1999) was digested with SacI and SmaI to excise nt 7300 to nt 7120 and re-ligated. The plasmids carrying the mutated GGAA box (EBSm), the AP1-like (AP1m), the Sp-1 site (Sp-1m) and both sites (EBSm/ AP1m) were prepared using the QuikChange site-directed mutagenesis kit (Stratagene). The sequences of the primers used to introduce the specific mutations were: EBSm 5'-CTCGCGAG CGTACGTGCCTCACATCGTGACGCACA-GCCCCCCTGG -3', Sp-1m 5'-CCCCCCTGGGGGCCG-GATTCTTGGCCAGGC -3', AP1/CREm 5'-CGTGCCT-CAGGAAGTGTGGTGCAGCCCCCCTG-3', AP1/CREm/ EBSm 5'-CGTGCCTCACATCGTGTGGTGCAGCCCCC-CTG-3'. The nucleotide sequence of each deleted or mutated region was confirmed by dideoxy DNA sequencing procedure using the Sequenase kit (Amersham International). The human cDNA of Ets-1 (a generous gift of Dr Naoyuki Taniguchi) was subcloned in the Rc/CMV expression vector and into the retroviral vector Pinco-GFP (Grignani et al., 1998) . The viral supernatant from the retroviral packaging cell lines phoenix was produced, as described (Grignani et al., 1998) .
Transfections and reporter gene assay FLC were harvested in the exponential growth phase, washed twice with cold PBS, resuspended at 10610 6 in 50 ml of cold PBS containing 10 mg of DNA and transfected by electroporation. A Bio-Rad gene pulser was used at the field strength of 0.350 kV/cm and capacitance of 25 mF. After transfection, cells were split and treated with control medium or 1.5% Me 2 SO for 48 h before preparation of cell extracts for luciferase assay. Transfection efficiency was monitored by cotransfection of 0.5 mg of CMV-LacZ plasmid. NIH3T3 was transfected as previously described (Marziali et al., 1997) . Stable transfectants Ets-1A and Ets-1B pools (human Ets-1 coding cDNA was a generous gift of Dr Naoyuki Taniguchi) were obtained after selection with 500 mg/ml of G418 for 3 weeks. Stably transduced K561/Ets-1 were selected for high levels of GFP expression detected by FACS analysis and cultured in RPMI medium supplemented with 10% FCS.
DNA electrophoretic mobility shift assay (EMSA)
Whole cell extracts were prepared as described previously (Marziali et al., 1997) . Binding reaction mixture (20 ml final volume) contained end-labeled double-stranded oligonucleotide probes (20 000 c.p.m.) in binding buffer (75 mM KCl, 20 mM Tris-HCl pH 7.5, 1 mM DTT), 1 mg BSA, 14% (v/v) glycerol, 0.5 mg poly(dI)-poly(dC). Total cell lysates (15 mg) or purified recombinant Ets-1 protein (kindly provided by Dr J Ghysdael) were added and the reaction mixture was incubated for 20 min at room temperature. Samples were electrophoresed in 5% polyacrylamide gel in 0.56Tris-borate/EDTA (TBE) buffer for 2 h at 200 V at 168C. For supershift analysis, total cell extracts were incubated with anti-PU.1 (Pharmingen), anti Fli-1 (Santa Cruz Biotechnology), anti Ets-1 (Rameil et al., 2000) (kindly provided by Dr Jacques Ghysdael) or anti c-fos and c-Jun (Santa Cruz Biotechnology) antibodies simultaneously to the addition of binding reaction. After 1 h incubation on ice, samples were subjected to electrophoresis. For competitions, a 200-fold molar excess of the cold oligonucleotide was added to the binding reaction. The sequences of the oligonucleotides used in these studies were as follows: EBS-TfR: 5'-GAGCGT-ACGTGCCTCAGGAAGTGACGCACAGC-3'; EBS/AP1/ CRE TfR: 5'-CGTGCCTCAGGAAGTGACGCACAGCC CCCCTG-3'; Ets cs: 5'-GATCTCGAGCAGGAAGTTC-GA-3'; CRE/ATF: 5'-AGAGATTGCCTGACGTCAGAG-AGCTAG-3'.
Western blot assay
To prepare cytoplasmic and nuclear cell extracts the cells were washed twice with cold PBS and once in TB buffer (20 mM HEPES pH 7.3, 110 mM K-acetate, 5 mM Naacetate, 2 mM Mg-acetate, 1 mM EGTA, 2 mM DTT and protease inhibitors). The pellet was resuspended in TB buffer containing 40 mg/ml of digitonin (BDH, Laboratory Supplies Pools), incubated 5 min on ice and centrifuged at 14 000 r.p.m. for 3 min to obtain cytoplasmic protein in the supernatant. The pellet was washed twice with buffer A (10 mM HEPES pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 1.5 mM DTT, 2 mM PMSF) and resuspended with buffer C (20 mM HEPES pH 7.9, 25% (v/v) glycerol, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 2 mM PMSF, 1.5 mM DTT) incubated for 30 min at +48C and centrifuged for 2 min to obtain nuclear protein.
For Western blot analysis 50 mg of whole, cytoplasmic or nuclear cell extracts were denatured and separated on 10% SDS -PAGE. Proteins were transferred onto nitrocellulose paper, incubated with a monoclonal anti Ets-1 antibody (Transduction Laboratories). For Ets-1 stably expressing FLC an anti Ets-1 antibody (Novocastra), specifically recognizing the human protein, was utilized.
Flow cytometry evaluation of TfR and Glycophorin A
The expression of CD71 (TfR) on FLC wild type or stably expressing Ets-1 cells was evaluated by flow cytometry using a rat anti-murine transferrin receptor monoclonal antibody conjugated with phycoerythrin (Clone C2, Becton-Dickinson/ Pharmingen). The expression of CD71 and Glycophorin A on K562/Pi and K562/Ets-1 was evaluated by flow cytometry using monoclonal antibodies conjugated with phycoerythrin (Becton-Dickinson/Pharmingen). Negative controls were labelled with an appropriate isotype-matched control immunoglobulin. Fluorescence intensity was evaluated with a FACS-SCAN (Becton-Dickinson) and the results were expressed in terms of mean fluorescence intensity.
RNA extraction and analysis
RNA was extracted and purified by the guanidium cesium chloride method (Glisin et al., 1974) . RNase protection was performed as previously described (Marziali et al., 1997) . To generate Ets-1 riboprobe, the cDNA was subcloned in pBsKS linearized with EcoRI and transcribed with T3 polymerase. For Northern blot analysis, RNA (20 mg) was run on denaturing agarose gels containing formaldehyde, transferred onto Hybond-N nylon membrane (Amersham), and hybridized to random primed 32 P-labeled (1.5610 6 c.p.m./ml) aglobin, TfR (Battistini et al., 1991) and b-actin cDNA probes. Levels of hybridization were quantified on a LKB densitometer and mRNA levels were evaluated relative to bactin.
Morphological analysis
Cytospin preparations of w.t. and transfected FLCs and K562 were stained with May -Gru¨nwald Giemsa and analysed under an Axiophot microscope (Zeiss, Jena, Germany) equipped with a digital system for image capture.
